The safety evaluation of FM101, an A3 adenosine receptor modulator, in rat, for developing as therapeutics of glaucoma and hepatitis

Authors

  • Chong-Woo Park R&D Center, Futuremedicine Co., Ltd., Seongnam, Republic of Korea; Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Seoul National University, Seoul, Republic of Korea
  • Chung-Tack Han Biotoxtech Co., Ltd., Cheongju, Republic of Korea
  • Yasue Sakaguchi Ina Research Inc., Ina, Japan
  • Jiyoun Lee R&D Center, Futuremedicine Co., Ltd., Seongnam, Republic of Korea
  • Hwa-Young Youn College of Veterinary Medicine, Seoul National University, Seoul, Republic of Korea, Telephone number: 82-2-880-1266, Fax number: 82-31-757-2738, E-mail: hyyoun@snu.ac.kr

DOI:

https://doi.org/10.17179/excli2019-2058

Keywords:

Adenosine, A3AR modulator, acute oral toxicity, 28-day subchronic toxicity

Abstract

Adenosine is a critical regulator of inflammation and fibrosis, it affects endogenous cell signaling via binding to the A3 adenosine receptor. FM101 is a potent, highly selective A3 adenosine receptor modulator that has been developed as a treatment for glaucoma and hepatitis. We determined that FM101 is a biased ligand with functional activities both as a G protein agonist and a β-arrestin antagonist. The safety of FM101 was evaluated by administering an acute dose in rats, the results indicated that the approximate lethal dose was greater than 2000 mg/kg. In a subchronic toxicity study, FM101 was administered orally once per day to rats at doses of 250, 500, and 1000 mg/kg/day over a period of 28 days. Abnormal posture, irregular respiration, decreased movement, and ear flushing were observed during the early phase of dosing, and loose stools were observed sporadically among the animals that received 500 and 1000 mg/kg/day. Body weight and food consumption were decreased in one male and one female rat in the 1000 mg/kg/day group during the first 2 weeks of observation. However, there were no test substance-related changes or adverse effects observed during our ophthalmological, clinical chemistry, urine, organ weight, and histopathological analysis. These findings indicate that no observed adverse effect level of FM101 was 1000 mg/kg/day in male and female rats.

Downloads

Published

2020-02-12

How to Cite

Park, C.-W., Han, C.-T., Sakaguchi, Y., Lee, J., & Youn, H.-Y. (2020). The safety evaluation of FM101, an A3 adenosine receptor modulator, in rat, for developing as therapeutics of glaucoma and hepatitis. EXCLI Journal, 19, 187–200. https://doi.org/10.17179/excli2019-2058

Issue

Vol. 19 (2020)

Section

Original articles

License

Authors who publish in this journal agree to the following terms:

  • The authors keep the copyright and grant the journal the right of first publication under the terms of the Creative Commons Attribution license, CC BY 4.0. This licencse permits unrestricted use, distribution and reproduction in any medium, provided that the original work is properly cited.
  • The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
  • Because the advice and information in this journal are believed to be true and accurate at the time of publication, neither the authors, the editors, nor the publisher accept any legal responsibility for any errors or omissions presented in the publication. The publisher makes no guarantee, express or implied, with respect to the material contained herein.
  • The authors can enter into additional contracts for the non-exclusive distribution of the journal's published version by citing the initial publication in this journal (e.g. publishing in an institutional repository or in a book).